Skip to Main Content

New research finds that the GLP-1 class of drugs — glucagon-like peptide receptor agonists — is more effective in mitigating the risk of 10 obesity-associated cancers than its type 2 diabetes drug alternatives.

The retrospective study, published Friday in JAMA Network Open, measured results for a cohort of more than 1.6 million patients with type 2 diabetes from 2005 to 2018 who were prescribed GLP-1s, insulin, or metformin. The researchers used data from the first time point, the prescription of any of the drugs, until up to 15 years after.


Rong Xu, a professor of biomedical informatics at Case Western Reserve University and study author, said the known efficacy of GLP-1 drugs in treating weight loss and managing type 2 diabetes prompted researchers to do the study.

STAT+ Exclusive Story


This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Already have an account? Log in



Totals $468 per year

$39/month Get Started

Totals $468 per year



for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month



Save 15%

$399/year Get Started

Save 15%

11+ Users


Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users


Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.


STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect

To submit a correction request, please visit our Contact Us page.